Christina Cudzewicz, PA
Surgical · Phoenix, AZNPI 1417508722
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,793 and has fallen 80.3% since, to $550 in 2025. Among surgical clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $35.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$744
- Pfizer$734
- Dendreon Pharmaceuticals LLC$728
- Sumitomo Pharma America, Inc.$603
- AstraZeneca$407
- Progenics Pharmaceuticals, Inc.$346
- plus $3K from 26 others
What the payments were for
- Food & beverage$6,40097%
- Education$1853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 18 | $744 |
| Pfizer | 19 | $734 |
| Dendreon Pharmaceuticals LLC | 15 | $728 |
| Sumitomo Pharma America, Inc. | 8 | $603 |
| AstraZeneca | 8 | $407 |
| Progenics Pharmaceuticals, Inc. | 7 | $346 |
| Astellas Pharma US Inc | 12 | $316 |
| AbbVie | 4 | $279 |
| Axonics, Inc. | 15 | $246 |
| Endo Pharmaceuticals Inc. | 6 | $217 |
| Urogen Pharma, Inc. | 3 | $182 |
| Tolmar Pharmaceuticals, Inc. | 12 | $181 |
| Tolmar, Inc. | 6 | $147 |
| Olympus America Inc. | 2 | $147 |
| Urovant Sciences Inc | 6 | $133 |
| Procept Biorobotics Corporation | 1 | $124 |
| Ferring Pharmaceuticals Inc. | 1 | $113 |
| Myriad Genetic Laboratories, Inc. | 6 | $111 |
| Boston Scientific | 5 | $102 |
| Teleflex LLC | 3 | $101 |
| Intuitive Surgical | 1 | $100 |
| Orthofix Medical, Inc. | 2 | $99 |
| Bayer | 6 | $98 |
| Merck | 4 | $96 |
| Coloplast | 3 | $55 |
| Blue Earth Diagnostics | 3 | $50 |
| Clarus Therapeutics Inc. | 2 | $29 |
| Tempus AI, Inc | 1 | $26 |
| 180 Medical, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$395
- PROVENGE$362
- JELMYTO$157
- XIAFLEX$148
- EPKINLY$145
- GEMTESA$142
- ORGOVYX$140
- iTIND System$129
- AKEEGA$129
- RYBREVANT$125
- CARVYKTI$125
- PYLARIFY$125
- AquaBeam Robotic System$124
- MYRBETRIQ$115
- ADSTILADRIN$113
- LYNPARZA$112
- TALZENNA$107
- XTANDI$107
- TUKYSA$100
- DAVINCI XI$100
How this compares
$6,585 in reported general payments places this provider in the 95th percentile of 271 surgical providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 21 | $20,320 |
| MyrbetriqMirabegron | 15 | $15,260 |
| Tamsulosin Hcl | 119 | $1,369 |
| Oxybutynin Chloride ErOxybutynin Chloride | 51 | $783 |
| Finasteride | 29 | $318 |
| Levofloxacin | 16 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $603 | $20,32021 claims |
| Astellas Pharma US IncMyrbetriq | $316 | $15,26015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 271 surgical providers in Arizona.
Other surgical in Phoenix
- Karla FrickPhoenix$38K
- Sarah MullerPhoenix$6K
- Britni FergusonPhoenix$6K
- Tyler KnudsenPhoenix$5K
- Anna LyonsPhoenix$4K
- Christina FriehPhoenix$4K
- Margaret HuntPhoenix$3K
- Richard BassettPhoenix$3K
- Lisa ReinertsonPhoenix$3K
- Emerald LassiterPhoenix$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.